A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Dalfampridine-D4 | CAS 26257-21-6 - Request Quote

Picture of Dalfampridine-D4

Dalfampridine-D4

SZ CAT No:SZ-D102D01
CAS No
26257-21-6
Mol.F.
C5H2D4N2
Mol.Wt.
98.1
Inv. Status
Synthesis on demand
Rel. CAS No26192-56-3 (HCl salt)

Chemical Name :

Shipping Temperature :

HSN Code :

Country of Origin :

Smiles :

Usage Note:

Dalfampridine-D4 is chemically Pyridin-d4-4-amine. Dalfampridine-D4 is supplied with detailed characterization data compliant with regulatory guideline. Dalfampridine-D4 can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Dalfampridine.

The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.

Applications & Regulatory Use Cases

Buy 26257-21-6

Purchase 26257-21-6

Order 26257-21-6

Enquire 26257-21-6

price of 26257-21-6

26257-21-6 Supplier

26257-21-6 Manufacturer

26257-21-6 Exporter

buy high quality Dalfampridine-D4

Purchase Dalfampridine-D4

Dalfampridine-D4 suppliers

Dalfampridine-D4 manufacturers

Dalfampridine-D4 price

Order Dalfampridine-D4

Enquire Dalfampridine-D4

Dalfampridine-D4 cost

Dalfampridine-D4 Supplier

Dalfampridine-D4 Distributor

Dalfampridine-D4 for Method Validation

Dalfampridine Reference Standard

Dalfampridine-D4 for ANDA Filing

Dalfampridine-D4 for Forced Degradation Studies

Dalfampridine-D4 Identification Standards

Dalfampridine-D4 for DMF Filing

ℹ️

Disclaimer

SynZeal product information given on this website is as per the existing understanding while publishing the details on website. The customer is responsible for assessing the accuracy of the information at the time of actual purchase.

SynZeal will update these details as per new developments or findings in product specifications without further notice.

,